ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries - Seite 2

About dolutegravir (Tivicay) 

Dolutegravir is an integrase strand transfer inhibitor (INSTI) for use in combination with other antiretroviral agents for the treatment of HIV. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection.

Tivicay is approved in over 70 countries across North America, Europe, Asia, Australia, Africa and Latin America. A regulatory application for dolutegravir is currently being evaluated by the China Food and Drug Administration (CFDA).

About Human Immunodeficiency Virus (HIV) in China

UNAIDS estimates that approximately 780,000 (620,000 to 940,000) people are infected with HIV/AIDS in China.  With more than 40,000 new HIV infections and over 25,000 deaths reported in 2011.^[1] People living with HIV/ AIDS in China who meet the national treatment criteria are referred to receive care through the China National Free Antiretroviral Treatment Programme (CNFATP).^[2] Still, only an estimated 126,000 people with HIV were receiving antiretroviral treatment, with an estimated 76% of adults and children who met the criteria receiving antiretroviral treatment.^[1]

About ViiV Healthcare 

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit http://www.viivhealthcare.com

About Desano Pharmaceuticals 

Founded in 1996, Desano Pharmaceutical is a leading vertically integrated pharmaceuticals company specialising in developing and manufacturing of generic ARV APIs and formulations with 4 manufacturing sites located in China approved by the agencies of CFDA, USFDA and WHO. Desano Pharmaceutical is one of the key ARV APIs suppliers for low to middle income countries, supporting over 4 million AIDS patients treatment. For more information, please visit http://www.desano.com